Background {#Sec1}
==========

Beyond neutralization, immunoglobulin G (IgG) has the capacity to recruit potent effector functions of the innate immune system through engagement with Fc gamma receptors (FcγRs), which are widely expressed throughout the haematopoietic system. Directly or indirectly, FcγRs mediate antiviral processes that include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), respiratory burst, antigen display, antibody production, cell activation, and release of inflammatory mediators \[[@CR1]\].

FcγR-mediated effector functions are increasingly recognized as a component of HIV-1 protective immunity \[[@CR2]\]. However, the role of these effector functions in modulating perinatal HIV-1 transmission risk is currently undefined. Given the contribution of FcγR-mediated effector functions to eliminating cell-free and cell-associated virus, these processes may modify the infectiousness of an HIV-1 infected mother. In addition, transplacental transferred anti-HIV-1 IgG may recruit innate immune effector functions in the foetus/infant through engaging FcγRs expressed on foetal/infant immune cells, and in this manner modify the infant's susceptibility to HIV-1 acquisition.

In vivo, FcγR-mediated effector functions are governed by a balance between activating and inhibitory FcγRs \[[@CR3]\]. This balance is perturbed by functionally significant genotypic variants that modulate cellular activation and ultimately effector function capability. These include gene duplication/deletion that affects FcγR surface density \[[@CR4], [@CR5]\] and amino acid changes that alter the receptor's binding affinity for antibody subclasses (FcγRIIa-H131R and FcγRIIIa-F158V) \[[@CR6], [@CR7]\], subcellular localization (FcγRIIb-I232T) \[[@CR8]\], glycosylation patterns (FcγRIIIb-HNA1a\|b\|c) \[[@CR9], [@CR10]\], and the expression of a functional molecule (FcγRIIc-X57Q and c.798+1A\>G) \[[@CR11], [@CR12]\].

Using these variants as a proxy for functional capability, this study indirectly assessed the potential role of FcγR-mediated effector functions in mother-to-child transmission of HIV-1. Due to the exploratory nature of the study, associations are reported unadjusted for multiple comparisons. However, adjusted associations were also considered. Our findings highlight a potential role for the FcγRIIIa-F158V variant in modulating maternal infectiousness, while in both mother and infant the FcγRIIIb-HNA1a\|b\|c variant associated with HIV-1 transmission.

Results {#Sec2}
=======

Cohort {#Sec3}
------

A nested case--control study was undertaken to investigate *FCGR* variability in HIV-1 infected mothers and their infants recruited as part of four perinatal cohorts at two hospitals in Johannesburg, South Africa \[[@CR13]\]. Overall, the four cohorts comprised 849 HIV-1 infected mothers and their infants, of whom 83 (10 %) acquired HIV-1 perinatally. In the present study, *FCGR* genotypic data from 79 HIV-1 infected mothers and 78 HIV-1 infected infants (transmitting cases) were compared with 234 HIV-1 infected mothers and 235 uninfected infants (non-transmitting controls). Mode of transmission was defined according to the presence/absence of detectable HIV-1 DNA in the infant at birth and 6 weeks of age. Infants that tested HIV-1 positive at 6 weeks of age, but who were negative at birth, were considered to be infected intrapartum (during labour and delivery), while infants that tested HIV-1 positive at birth were considered infected in utero. Infants that were HIV-1 positive at 6 weeks, but had no birth sample, were categorized as 'undetermined'. Since 25/28 (89.2 %) mothers in the 'undetermined' category received drug interventions known to reduce intrapartum transmission \[[@CR14]--[@CR16]\], it was concluded that the majority of infants in this group were likely infected in utero and was thus combined with the in utero group to form an in utero-enriched group.

Transmitting mothers had significantly higher HIV-1 plasma viral loads and lower CD4^+^ T cell counts compared to non-transmitting mothers (Table [1](#Tab1){ref-type="table"}). In addition, infants infected in utero had a significantly lower mean birth weight compared to exposed-uninfected infants. Maternal age, parity, mode of delivery, gestation, child sex, and reported breast feeding did not differ significantly between transmitting mothers (total, intrapartum or in utero) and non-transmitting mothers.Table 1Demographic and clinical characteristics of mothers and infantsMaternal viral load (log~10~ copies/ml)Non-transmitting (*N* = 234)^a^Total transmitting (*N* = 79)Intrapartum transmitting (*N* = 31)In utero transmitting (*N* = 20)^b^In utero-enriched transmitting (*N* = 48)N^c^N^c^N^c^N^c^N^c^Median (IQR)2184.08 (3.20--4.67)714.77 (3.77--5.34)\*\*\*274.77 (3.77--5.26)\*\*184.89 (4.20--5.47)\*\*\*444.81 (3.78--5.44)\*\*\*Maternal CD4^+^ T cell count Mean (std)217520 (275)70418 (222)\*\*27402 (179)\*15409 (276)43428 (247)\*Maternal age (years) Mean (std)23226.9 (5.1)7827.6 (5.2)3026.7 (5.0)2027.5 (5.5)4828.2 (5.2)Parity Mean (std)2312.1 (1.0)772.3 (1.2)292.3 (1.2)202.2 (1.2)482.3 (1.2)Mode of delivery \[N (%)\] Caesarean section23217 (7.3)7710 (13.0)292 (6.9)203 (15.0)488 (16.7)Gestation \[*N* (%)\] Preterm \<37 weeks21527 (12.6)7012 (17.1)257 (28.0)194 (21.1)455 (11.1)Child sex \[*N* (%)\] Male234101 (43.1)7939 (49.4)3118 (58.0)208 (40.0)4821 (43.8)Birth weight (g) Mean (std)2312980 (453)782889 (442)302943 (400)202784 (320)\*482856 (468)Breast fed *N* (%) \>3 days23334 (14.6)7810 (12.8)305 (16.7)202 (10.0)485 (10.4)Antiretrovirals Nevirapine234114 (48.7)7947 (59.5)3111 (35.5)2013 (65.0)4836 (75.0)\*\* Triple drug therapy2346 (2.6)792 (2.5)310200482 (4.2) Other drugs^d^23411 (4.7)796 (7.6)313 (9.7)201 (5.0)483 (6.3)For comparisons with non-transmitting mothers: \* P \< 0.05; \*\* P \< 0.01; \*\*\* P \< 0.001^a^Five unmatched mothers^b^One unmatched mother^c^Number of participants for whom data were available^d^Different regimens of zidovudine (AZT) and lamivudine (3TC)

Variants not detected in the study cohort {#Sec4}
-----------------------------------------

The FcγRIIb 2B.4 promoter haplotype (c.-386C/c.-120A) and expression of functional FcγRIIc are rare to absent in Black South African individuals \[[@CR17]\]. Accordingly, in the present cohort of Black South African mothers and infants, none possessed the FcγRIIb 2B.4 promoter haplotype. Furthermore, despite 84/313 (25.3 %) mothers and 81/313 (25.9 %) infants bearing an FcγRIIc-Q57 allele, only one non-transmitting mother expressed functional FcγRIIc as predicted by the *FCGR2C* c.798+1A\>G splice-site variant \[[@CR12]\].

*FCGR* copy number variability {#Sec5}
------------------------------

The frequency of *FCGR3A* gene copy number variability (CNV) was low, occurring in 17/313 (5.4 %) mothers and 14/313 (4.5 %) infants (Fig. [1](#Fig1){ref-type="fig"}), and did not associate with perinatal HIV-1 transmission (P \> 0.05 for all comparisons; Additional file [1](#MOESM1){ref-type="media"}: Table S1). *FCGR3B* gene CNV was observed more frequently in 92/313 (29.4 %) mothers and 100/313 (31.9 %) infants (Fig. [1](#Fig1){ref-type="fig"}). The overall distribution of *FCGR3B* gene copy number was significantly different between exposed-uninfected infants and intrapartum infected infants (P = 0.029), with the intrapartum infected group having fewer *FCGR3B* gene duplications and no gene deletions (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Maternal *FCGR3B* gene CNV did not associate with HIV-1 transmission (P \> 0.05 for all comparisons; Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 1The distribution of *FCGR3A* and *FCGR3B* gene copy number in HIV-1 infected mothers (**a**, **b**, respectively) and their infants (**c**, **d**, respectively)

FcγR variants and infectiousness of the transmitter/mother {#Sec6}
----------------------------------------------------------

To determine if FcγR variants were associated with the infectiousness of the mother, HIV-1 transmission was assessed according to maternal genotypes and allele carriage in a univariate and multivariate model (Table [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, respectively). Overall, the maternal FcγRIIIa-F158V variant significantly associated with HIV-1 transmission (P = 0.017), while a trend was observed for the FcγRIIIb-HNA1a\|b\|c variant (P = 0.058).Table 2FcγR genotypes and allele carriage in HIV-1 non-transmitting and transmitting mothersNon-transmittingTotal transmittingIntrapartum transmittingN (%)N (%)OR (95 % CI)P valueP~Bonf~N (%)OR (95 % CI)P valueP~Bonf~*FcγRIIa (rs1801274)*Overall associationP = 0.379nsP = 0.688nsGenotype 131HH (ref)60 (25.6)15 (19.0)16 (19.4)1 131HR106 (45.3)36 (45.6)1.36 (0.69--2.68)P = 0.378ns14 (45.2)1.32 (0.48--3.62)P = 0.558ns 131RR68 (29.1)28 (35.4)1.65 (0.80--3.37)P = 0.172ns11 (35.5)1.62 (0.56--4.64)P = 0.371nsAllele carriage ≥1 131H allele166 (70.9)51 (64.6)0.75 (0.43--1.28)P = 0.288ns20 (64.5)0.74 (0.34--1.64)P = 0.464ns ≥1 131R allele174 (74.4)64 (81.0)1.47 (0.78--2.77)P = 0.233ns25 (80.6)1.44 (0.56--3.67)P = 0.449ns*FcγRIIb (rs1050501)*Overall associationP = 0.194nsP = 0.397nsGenotype 232II (ref)113 (48.3)32 (40.5)112 (38.7)1 232IT103 (44.0)36 (45.6)1.23 (0.71--2.13)P = 0.450ns15 (48.4)1.37 (0.61--3.07)P = 0.442ns 232TT18 (7.7)11 (13.9)2.16 (0.93--5.03)P = 0.075ns4 (12.9)2.09 (0.61--7.20)P = 0.242nsAllele carriage ≥1 232I allele216 (92.3)68 (86.3)0.52 (0.23--1.14)P = 0.103ns27 (87.1)0.56 (0.18--1.79)P = 0.239ns ≥1 232T allele121 (51.7)47 (59.5)1.37 (0.82--2.30)P = 0.231ns19 (61.3)1.48 (0.69--3.18)P = 0.317ns*FcγRIIIa (rs396991)*Overall associationP = 0.017nsP = 0.380nsGenotype 158F/FF/FF (ref)76 (32.5)40 (50.6)110 (32.3)1 158FV/FFV/FVV121 (51.7)31 (39.2)0.49 (0.28--0.84)*P* *=* *0.010*ns19 (61.3)1.19 (0.53--2.70)P = 0.672ns 158V/VV36 (15.4)8 (10.1)0.41 (0.17--0.97)*P* *=* *0.041*ns2 (6.5)0.41 (0.09--1.97)P = 0.266nsAllele carriage ≥1 158F allele197 (84.2)71 (89.9)1.67 (0.74--3.75)P = 0.217ns29 (93.5)2.72 (0.62--11.91)P = 0.183ns ≥1 158V allele157 (67.1)39 (49.4)0.47(0.28--0.79)*P* *=* *0.004*ns21 (67.7)1.01 (0.45--2.25)P = 0.980ns*FcγRIIIb*Overall associationP = 0.058nsP = 0.647nsGenotype HNA1a+/1b−/1c−51 (21.8)13 (16.5)0.68 (0.32--1.44)P = 0.315ns4 (12.9)0.51 (0.15--1.70)P = 0.276ns HNA1a−/1b+/1c−23 (9.8)7 (8.9)0.81 (0.31--2.11)P = 0.668ns4 (12.9)1.14 (0.33--3.92)P = 0.837ns HNA1a−/1b−/1c+13 (5.6)0 (0)--0 (0)-- HNA1a+/1b+/1c− (ref)72 (30.8)27 (34.2)111 (35.5)1 HNA1a+/1b−/1c+40 (17.1)11 (13.9)0.73 (0.33--1.63)P = 0.448ns5 (16.1)0.82 (0.27--2.52)P = 0.727ns HNA1a−/1b+/1c+22 (9.4)17 (21.5)2.06 (0.95--4.46)P = 0.066ns5 (16.1)1.49 (0.47--4.75)P = 0.502ns HNA1a+/1b+/1c+12 (5.1)4 (5.1)0.89 (0.26--3.00)P = 0.849ns2 (6.5)1.09 (0.21--5.54)P = 0.916nsAllele carriage ≥1 HNA1a allotype175 (74.8)55 (69.6)0.77 (0.44--1.36)P = 0.369ns22 (71.0)0.82 (0.36--1.89)P = 0.648ns ≥1 HNA1b allotype129 (55.1)55 (69.6)1.87 (1.08--3.21)*P* *=* *0.025*ns22 (71.0)1.99 (0.88--4.50)P = 0.099ns ≥1 HNA1c allotype87 (37.2)32 (40.5)1.15 (0.68--1.94)P = 0.599ns12 (38.7)1.07 (0.49--2.30)P = 0.869nsIn utero transmittingIn utero-enriched transmittingN (%)OR (95 % CI)P valueP~Bonf~N (%)OR (95 % CI)P valueP~Bonf~*FcγRIIa (rs1801274)*P = 0.182nsP = 0.545nsGenotype 131HH (ref)2 (10.0)19 (18.8)1 131HR9 (45.0)2.55 (0.53--12.17)P = 0.241ns22 (45.8)1.38 (0.60--3.20)P = 0.447ns 131RR9 (45.0)3.97 (0.83--19.10)P = 0.085ns17 (35.4)1.67 (0.69--4.02)P = 0.225nsAllele carriage ≥1 131H allele11 (55.0)0.50 (0.20--1.26)P = 0.143ns31 (64.6)0.75 (0.39--1.44)P = 0.383ns ≥1 131R allele18 (90.0)3.10 (0.70--13.77)P = 0.136ns39 (81.3)1.49 (0.68--3.27)P = 0.314ns*FcγRIIb (rs1050501)*P = 0.125nsP = 0.274nsGenotype 232II (ref)10 (50.0)120 (41.7)1 232IT6 (30.0)0.66 (0.23--1.87)P = 0.434ns21 (43.8)1.15 (0.59--2.25)P = 0.678ns 232TT4 (20.0)2.51 (0.71--8.87)P = 0.153ns7 (14.6)2.20 (0.81--5.94)P = 0.121nsAllele carriage ≥1 232I allele16 (80.0)0.33 (0.10--1.10)P = 0.072ns41 (85.4)0.49 (0.19--1.24)P = 0.133ns ≥1 232T allele10 (50.0)0.93 (0.37--2.33)P = 0.883ns28 (58.3)1.31 (0.70--2.45)P = 0.403ns*FcγRIIIa (rs396991)*P = 0.137ns*P* *=* *0.00040.017*Genotype 158F/FF/FF (ref)11 (55.0)130 (62.5)1 158FV/FFV/FVV8 (40.0)0.46 (0.18--1.19)P = 0.108ns12 (25.0)0.25 (0.12--0.52)*P* *=* *0.00010.004* 158V/VV1 (5.0)0.19 (0.02--1.50)P = 0.115ns6 (12.5)0.41 (0.16--1.07)P = 0.069nsAllele carriage ≥1 158F allele19 (95.0)3.57 (0.46--27.48)P = 0.222ns42 (87.5)1.31 (0.52--3.31)P = 0.562ns ≥1 158V allele9 (45.0)0.39 (0.16--0.99)*P* *=* *0.048*ns18 (37.5)0.29 (0.15--0.55)*P* *=* *0.00010.004FcγRIIIb*P = 0.320nsP = 0.123nsGenotype HNA1a+/1b−/1c−6 (30.0)2.82 (0.67--11.82)P = 0.155ns9 (18.8)0.79 (0.33--1.94)P = 0.612ns HNA1a−/1b+/1c−1 (5.0)1.04 (0.10--10.53)P = 0.971ns3 (6.3)0.59 (0.16--2.20)P = 0.429ns HNA1a−/1b−/1c+0 (0)--0 (0)-- HNA1a+/1b+/1c− (ref)3 (15.0)116 (33.3)1 HNA1a+/1b−/1c+4 (20.0)2.40 (0.51--11.26)P = 0.267ns6 (12.5)0.68 (0.24--1.86)P = 0.448ns HNA1a−/1b+/1c+5 (25.0)5.45 (1.21--24.66)*P* *=* *0.028*ns12 (25.0)2.45 (1.01--5.96)*P* *=* *0.047*ns HNA1a+/1b+/1c+1 (5.0)2.00 (0.19--20.85)P = 0.562ns2 (4.2)0.75 (0.15--3.68)P = 0.723nsAllele carriage ≥1 HNA1a allotype14 (70.0)0.79 (0.29--2.14)P = 0.638ns33 (68.8)0.74 (0.38--1.46)P = 0.388ns ≥1 HNA1b allotype10 (50.0)0.81 (0.33--2.03)P = 0.659ns33 (68.8)1.79 (0.92--3.47)P = 0.085ns ≥1 HNA1c allotype10 (50.0)1.69 (0.68--4.22)P = 0.262ns20 (41.7)1.21 (0.64--2.27)P = 0.560nsP values less than 0.05 are indicated in italics*P* ~*Bonf*~ Bonferroni corrected P value, *OR* odds ratio, *CI* confidence interval, *ns* not statistically significant, --, the variable of interest was not detected in any of the cases and thus could not be analysedTable 3Maternal FcγR variants associated with perinatal HIV-1 transmission after adjusting for confounding variablesTotal transmittingIntrapartum transmittingUnivariateAdjusted for VL^a^P~Bonf~UnivariateAdjusted for VLP~Bonf~AOR (95 % CI)P valueAOR (95 % CI)P value*FcγRIIa (rs1801274)*Genotype 131HH (ref)11 131HRP = 0.3781.81 (0.82--3.99)P = 0.141nsP = 0.5581.43 (0.46--4.46)P = 0.539ns 131RRP = 0.1722.59 (1.14--5.87)*P* *=* *0.023*nsP = 0.3712.57 (0.80--8.26)P = 0.113nsAllele carriage ≥1 131H alleleP = 0.2880.58 (0.33--1.05)P = 0.071nsP = 0.4640.49 (0.21--1.16)P = 0.106ns ≥1 131R alleleP = 0.2332.11 (1.00--4.42)*P* *=* *0.049*nsP = 0.4491.82 (0.64--5.23)P = 0.263ns*FcγRIIb (rs1050501)*Genotype 232II (ref)11 232ITP = 0.4501.29 (0.71--2.35)P = 0.408nsP = 0.4421.60 (0.65--3.93)P = 0.309ns 232TTP = 0.0752.80 (1.11--7.10)*P* *=* *0.030*nsP = 0.2423.25 (0.87--12.17)P = 0.080nsAllele carriage ≥1 232I alleleP = 0.1030.41 (0.17--0.97)*P* *=* *0.043*nsP = 0.2390.40 (0.12--1.33)P = 0.133ns ≥1 232T alleleP = 0.2311.49 (0.84--2.62)P = 0.171nsP = 0.3171.81 (0.77--4.28)P = 0.175ns*FcγRIIIa (rs396991)*Genotype 158F/FF/FF (ref)11 158FV/FFV/FVV*P* *=* *0.010*0.51 (0.28--0.92)*P* *=* *0.026*nsP = 0.6721.09 (0.45--2.64)P = 0.850ns 158V/VV*P* *=* *0.041*0.30 (0.11--082)*P* *=* *0.018*nsP = 0.2660.20 (0.02--1.70)P = 0.141nsAllele carriage ≥1 158F alleleP = 0.2172.29 (0.89--5.88)P = 0.084nsP = 0.1835.22 (0.67--40.41)P = 0.114ns ≥1 158V allele*P* *=* *0.004*0.46 (0.26--0.82)*P* *=* *0.008*nsP = 0.9800.89 (0.37--2.12)P = 0.786ns*FcγRIIIb*Genotype HNA1a+/1b−/1c−P = 0.3150.47 (0.20--1.10)P = 0.083nsP = 0.2760.45 (0.12--1.61)P = 0.218ns HNA1a−/1b+/1c−P = 0.6680.90 (0.33--2.46)P = 0.839nsP = 0.8371.31 (0.35--4.87)P = 0.683ns HNA1a−/1b−/1c+-------- HNA1a+/1b+/1c− (ref)11 HNA1a+/1b−/1c+P = 0.4480.63 (0.26--1.51)P = 0.300nsP = 0.7270.68 (0.19--2.42)P = 0.547ns HNA1a−/1b+/1c+P = 0.0661.37 (0.59--3.19)P = 0.466nsP = 0.5021.20 (0.35--4.15)P = 0.777ns HNA1a+/1b+/1c+P = 0.8490.42 (0.10--1.71)P = 0.226nsP = 0.9160.42 (0.05--3.72)P = 0.433nsAllele carriage ≥1 HNA1a allotypeP = 0.3690.78 (0.43--1.44)P = 0.433nsP = 0.6480.73 (0.30--1.75)P = 0.481ns ≥1 HNA1b allotype*P* *=* *0.025*2.11 (1.16--3.85)*P* *=* *0.014*nsP = 0.0992.18 (0.90--5.33)P = 0.086ns ≥1 HNA1c allotypeP = 0.5990.95 (0.54--1.68)P = 0.865nsP = 0.8690.88 (0.38--2.04)P = 0.759nsIn utero transmittingIn utero-enriched transmittingUnivariateAdjusted for VL + bwtP~Bonf~UnivariateAdjusted for VLP~Bonf~AOR (95 % CI)P valueAOR (95 % CI)P value*FcγRIIa (rs1801274)*Genotype 131HH (ref)11 131HRP = 0.2415.74 (0.66--49.93)P = 0.113nsP = 0.4472.28 (0.84--6.17)P = 0.105ns 131RRP = 0.08511.46 (1.29--101.86)*P* *=* *0.029*nsP = 0.2252.82 (1.01--7.89)*P* *=* *0.048*nsAllele carriage ≥1 131H alleleP = 0.1430.34 (0.12--0.97)*P* *=* *0.045*nsP = 0.3830.63 (0.32--1.27)P = 0.200ns ≥1 131R alleleP = 0.1367.65 (0.94--62.32)P = 0.057nsP = 0.3142.50 (0.97--6.40)P = 0.057ns*FcγRIIb (rs1050501)*Genotype 232II (ref)1 232ITP = 0.4340.67 (0.22--2.06)P = 0.487nsP = 0.6781.15 (0.56--2.35)P = 0.707ns 232TTP = 0.1533.38 (0.73--15.61)P = 0.119nsP = 0.1212.57 (0.85--7.74)P = 0.094nsAllele carriage ≥1 232I alleleP = 0.0720.25 (0.06--1.07)P = 0.062nsP = 0.1330.42 (0.15--1.18)P = 0.100ns ≥1 232T alleleP = 0.8830.93 (0.34--2.54)P = 0.891nsP = 0.4031.33 (0.67--2.61)P = 0.412ns*FcγRIIIa (rs396991)*Genotype 158F/FF/FF (ref)11 158FV/FFV/FVVP = 0.1080.60 (0.21--1.71)P = 0.341ns*P* *=* *0.0001*0.29 (0.14--0.63)*P* *=* *0.002*ns 158V/VVP = 0.1150.19 (0.02--1.68)P = 0.135nsP = 0.0690.34 (0.11--0.98)*P* *=* *0.046*nsAllele carriage ≥1 158F alleleP = 0.2224.01 (0.48--33.16)P = 0.198nsP = 0.5621.71 (0.61--4.80)P = 0.305ns ≥1 158V allele*P* *=* *0.048*0.50 (0.18--1.36)P = 0.174ns*P* *=* *0.0001*0.31 (0.15--0.62)*P* *=* *0.0010.042FcγRIIIb*Genotype HNA1a+/1b−/1c−P = 0.1551.44 (0.30--6.85)P = 0.644nsP = 0.6120.45 (0.16--1.24)P = 0.124ns HNA1a−/1b+/1c−P = 0.9711.26 (0.12--13.63)P = 0.851nsP = 0.4290.66 (0.17--2.56)P = 0.544ns HNA1a−/1b−/1c+-------- HNA1a+/1b+/1c− (ref)11 HNA1a+/1b−/1c+P = 0.2671.88 (0.37--9.46)P = 0.442nsP = 0.4480.59 (0.20--1.68)P = 0.321ns HNA1a−/1b+/1c+*P* *=* *0.028*3.10 (0.60--15.95)P = 0.177ns*P* *=* *0.047*1.53 (0.58--4.02)P = 0.388ns HNA1a+/1b+/1c+P = 0.5621.10 (0.10--12.45)P = 0.939nsP = 0.7230.44 (0.08--2.28)P = 0.326nsAllele carriage ≥1 HNA1a allotypeP = 0.6380.85 (0.28--2.63)P = 0.783nsP = 0.3880.79 (0.38--1.64)P = 0.523ns ≥1 HNA1b allotypeP = 0.6591.09 (0.39--3.02)P = 0.868nsP = 0.0852.23 (1.08--4.62)*P* *=* *0.031*ns ≥1 HNA1c allotypeP = 0.2621.51 (0.55--4.14)P = 0.420nsP = 0.5601.04 (0.53--2.06)P = 0.904ns^a^The multivariate analysis adjusted for demographic and clinical variables that independently associated with transmission. Due to high correlation with viral load, CD4 T cell counts were not included in the multivariate modelP values less than 0.05 are indicated in italics*P* ~*Bonf*~ Bonferroni corrected P value, *AOR* adjusted odds ratio, *CI* confidence interval, *VL* viral load, *bwt* birth weight, *ns* not statistically significant, --, the variable of interest was not detected in any of the cases and thus could not be analysed

Carriage of at least one maternal FcγRIIIa-158V allele (confers enhanced antibody binding affinity) associated with a reduced odds of perinatal HIV-1 transmission (OR 0.47, 95 % CI 0.28--0.79, P = 0.004). When analysed according to mode of transmission, a similar association was observed for the in utero transmitting group (OR 0.39, 95 % CI 0.16--0.99, P = 0.048) and in utero-enriched transmitting group (OR 0.29, 95 % CI 0.15--0.55, P = 0.0001), but not for the intrapartum transmitting group (OR 1.01, 95 % CI 0.45--2.25, P = 0.980). These associations remained significant for the total transmitting group and in utero-enriched group in the multivariate analysis (P = 0.008 and P = 0.001, respectively) and for the in utero-enriched group after adjustment for multiple comparisons (univariate: P~Bonf~ = 0.004; multivariate: P~Bonf~ = 0.042).

Possession of an FcγRIIIb-HNA1b allele (modulates neutrophil function) significantly associated with an increased odds of HIV-1 transmission in both the univariate analysis (OR 1.87, 95 % CI 1.08--3.21, P = 0.025) and multivariate analysis (P = 0.014). A similar association was observed for the FcγRIIIb-HNA1b\|1c genotype in the in utero transmitting group (OR 5.45, 95 % CI 1.21--24.66, P = 0.028) and in utero-enriched transmitting group (OR 2.45, 95 % CI 1.01--5.96, P = 0.047). However, these associations were not significant in the multivariate analysis.

The FcγRIIa-H131R and FcγRIIb-I232T variants did not associate with perinatal HIV-1 transmission in the univariate analysis. However, after adjustment for confounding variables, the FcγRIIa-131RR genotype (receptor has reduced affinity for IgG2) and FcγRIIb-232TT genotype (confers reduced inhibitory capacity) associated with increased odds of HIV-1 transmission (Table [3](#Tab3){ref-type="table"}).

FcγR variants and susceptibility of the recipient/infant {#Sec7}
--------------------------------------------------------

In addition to an association observed in the mother, the infant FcγRIIIb-HNA1a\|b\|c variant also associated with susceptibility to HIV-1 acquisition in the infant (P = 0.046). In particular, carriage of least one FcγRIIIb-HNA1b allotype significantly associated with increased susceptibility to HIV-1 acquisition in the univariate analysis (OR 1.91, 95 % CI 1.11--3.30, P = 0.020; Table [4](#Tab4){ref-type="table"}) and multivariate analysis (P = 0.019; Table [5](#Tab5){ref-type="table"}). Conversely, homozygosity for the FcγRIIIb-HNA1a allotype associated with reduced odds of HIV-1 acquisition in the total infected group (OR 0.42, 95 % CI 0.18--0.96, P = 0.040) and intrapartum infected group (OR 0.19, 95 % CI 0.04--0.89, P = 0.035). The protective effect of FcγRIIIb-HNA1a homozygosity was also observed when compared to other allotype combinations, however not all comparisons remained significant in the multivariate analysis (Additional file [2](#MOESM2){ref-type="media"}: Table S2).Table 4FcγR genotypes and allele carriage in HIV-1 exposed-uninfected and infected infantsExposed-uninfectedTotal infectedIntrapartum infectedN (%)N (%)OR (95 % CI)P valueP~Bonf~N (%)OR (95 % CI)P valueP~Bonf~*FcγRIIa (rs1801274)*Overall associationP = 0.704nsP = 0.907nsGenotype 131HH (ref)47 (20.0)19 (24.4)17 (22.6)1 131HR116 (49.4)36 (46.2)0.77 (0.40--1.47)P = 0.426ns14 (45.2)0.81 (0.31--2.13)P = 0.670ns 131RR72 (30.6)23 (29.5)0.79 (0.39--1.61)P = 0.516ns10 (32.3)0.93 (0.33--2.62)P = 0.895nsAllele carriage ≥1 131H allele163 (69.4)55 (70.5)1.06 (0.60--1.85)P = 0.848ns21 (67.7)0.93 (0.42--2.07)P = 0.854ns ≥1 131R allele188 (80.0)59 (75.6)0.76 (0.42--1.43)P = 0.414ns24 (77.4)0.86 (0.35--2.11)P = 0.737ns*FcγRIIb (rs1050501)*Overall associationP = 0.278nsP = 0.773nsGenotype 232II (ref)116 (49.4)33 (42.3)114 (45.2)1 232IT90 (38.3)30 (38.5)1.17 (0.67--2.06)P = 0.583ns12 (38.7)1.10 (0.49--2.51)P = 0.811ns 232TT29 (12.3)15 (19.2)1.82 (0.87--3.79)P = 0.110ns5 (16.1)1.43 (0.48--4.29)P = 0.525nsAllele carriage ≥1 232I allele206 (86.8)63 (78.6)0.59 (0.30--1.17)P = 0.132ns26 (83.9)0.73 (0.26--2.06)P = 0.554ns ≥1 232T allele119 (47.2)45 (55.7)1.33 (0.79--2.23)P = 0.280ns17 (54.8)1.18 (0.56--2.51)P = 0.660ns*FcγRIIIa (rs396991)*Overall associationP = 0.339nsP = 0.964nsGenotype 158F/FF/FF (ref)86 (36.6)34 (43.6)112 (38.7)1 158FV/FFV/FVV118 (50.2)38 (48.7)0.81 (0.47--1.40)P = 0.456ns15 (48.4)0.91 (0.41--2.04)P = 0.821ns 158V/VV31 (13.2)6 (7.7)0.49 (0.19--1.28)P = 0.145ns4 (12.9)0.92 (0.28--3.08)P = 0.899nsAllele carriage ≥1 158F allele194 (82.6)72 (92.3)0.75 (0.44--1.26)P = 0.272ns27 (87.1)0.91 (0.42--1.97)P = 0.819ns ≥1 158V allele149 (63.4)44 (56.4)1.82 (0.73--4.55)P = 0.198ns19 (61.3)1.03(0.34--3.13)P = 0.964ns*FcγRIIIb*Overall association*P* *=* *0.046*ns*P* *=* *0.023*nsGenotype HNA1a+/1b−/1c−58 (24.7)9 (11.5)0.42 (0.18--0.96)*P* *=* *0.040*ns2 (6.5)0.19(0.04--0.89)*P* *=* *0.035*ns HNA1a−/1b+/1c−25 (10.6)7 (9.0)0.76 (0.29--1.95)P = 0.565ns1 (3.2)0.22 (0.03--1.81)P = 0.160ns HNA1a−/1b−/1c+14 (6.0)4 (5.1)0.77 (0.23--2.55)P = 0.672ns0 (0)-- HNA1a+/1b+/1c− (ref)73 (31.2)27 (34.6)113 (41.9)1 HNA1a+/1b−/1c+36 (15.3)11 (14.1)0.83 (0.37--1.85)P = 0.643ns7 (22.6)1.09 (0.40--2.97)P = 0.863ns HNA1a−/1b+/1c+22 (9.4)13 (16.7)1.60 (0.71--3.61)P = 0.260ns7 (22.6)1.79 (0.63--5.03)P = 0.272ns HNA1a+/1b+/1c+7 (3.0)7 (9.0)2.70 (0.87--8.43)P = 0.086ns1 (3.2)0.80 (0.09--7.07)P = 0.843nsAllele carriage ≥1 HNA1a allotype174 (74.0)54 (69.2)0.79 (0.45--1.38)P = 0.408ns23 (74.2)1.01 (0.43--2.37)P = 0.986ns ≥1 HNA1b allotype127 (54.0)54 (69.2)1.91 (1.11--3.30)*P* *=* *0.020*ns22 (71.0)2.08 (0.92--4.70)P = 0.079ns ≥1 HNA1c allotype79 (33.6)35 (44.9)1.61 (0.95--2.71)P = 0.075ns15 (48.4)1.85 (0.87--3.94)P = 0.110nsIn utero infectedIn utero-enriched infectedN (%)OR (95 % CI)P valueP~Bonf~N (%)OR (95 % CI)P valueP~Bonf~*FcγRIIa (rs1801274)*P = 0.265nsP = 0.693nsGenotype 131HH (ref)4 (21.1)112 (25.5)1 131HR6 (31.6)0.61 (0.16--2.25)P = 0.456ns22 (46.8)0.74 (0.34--1.62)P = 0.455ns 131RR9 (47.4)1.47 (0.43--5.04)P = 0.541ns13 (27.7)0.71 (0.30--1.68)P = 0.433nsAllele carriage ≥1 131H allele10 (52.6)0.49 (0.19--1.26)P = 0.139ns34 (72.3)1.16 (0.58--2.32)P = 0.685ns ≥1 131R allele15 (78.9)0.94 (0.30--2.96)P = 0.912ns35 (74.5)0.73 (0.35--1.51)P = 0.396ns*FcγRIIb (rs1050501)*P = 0.083nsP = 0.218nsGenotype 232II (ref)7 (36.8)119 (40.4)1 232IT6 (31.6)1.10 (0.36--3.40)P = 0.862ns18 (38.3)1.22 (0.61--2.46)P = 0.577ns 232TT6 (31.6)3.43 (1.07--10.98)*P* *=* *0.038*ns10 (21.3)2.11 (0.88--5.01)P = 0.092nsAllele carriage ≥1 232I allele13 (68.4)0.31 (0.11--0.87)*P* *=* *0.026*ns37 (78.7)0.52 (0.23--1.16)P = 0.110ns ≥1 232T allele12 (63.2)1.67 (0.64--4.39)P = 0.298ns28 (59.6)1.44 (0.76--2.71)P = 0.264ns*FcγRIIIa (rs396991)*P = 0.711nsP = 0.145nsGenotype 158F/FF/FF (ref)9 (47.4)122 (46.8)1 158FV/FFV/FVV8 (42.1)0.65 (0.24--1.75)P = 0.391ns23 (48.9)0.76 (0.40--1.46)P = 0.410ns 158V/VV2 (10.5)0.62 (0.13--3.01)P = 0.550ns2 (4.3)0.25 (0.06--1.14)P = 0.073nsAllele carriage ≥1 158F allele17 (89.5)0.64 (0.25--1.64)P = 0.354ns45 (95.7)0.66 (0.35--1.23)P = 0.190ns ≥1 158V allele10 (52.6)1.29 (0.28--5.87)P = 0.740ns25 (53.2)3.42 (0.79--14.81)P = 0.100ns*FcγRIIIb*P = 0.182nsP = 0.079nsGenotype HNA1a+/1b−/1c−3 (15.8)0.76 (0.17--3.29)P = 0.709ns7 (14.9)0.63 (0.24--1.66)P = 0.350ns HNA1a−/1b+/1c−1 (5.3)0.58 (0.07--5.24)P = 0.631ns6 (12.8)1.25 (0.43--3.61)P = 0.678ns HNA1a−/1b−/1c+1 (5.3)1.04 (0.11--9.62)P = 0.970ns4 (8.5)1.49 (0.43--5.20)P = 0.532ns HNA1a+/1b+/1c− (ref)5 (26.3)114 (29.8)1 HNA1a+/1b−/1c+2 (10.5)0.81 (0.15--4.39)P = 0.808ns4 (8.5)0.58 (0.18--1.89)P = 0.365ns HNA1a−/1b+/1c+5 (26.3)3.32 (0.88--12.52)P = 0.077ns6 (12.8)1.42 (0.49--4.14)P = 0.518ns HNA1a+/1b+/1c+2 (10.5)4.17 (0.68--25.59)P = 0.123ns6 (12.8)4.47 (1.30--15.31)*P* *=* *0.017*nsAllele carriage ≥1 HNA1a allotype12 (63.2)0.60 (0.23--1.60)P = 0.307ns31 (66.0)0.70 (0.35--1.33)P = 0.258ns ≥1 HNA1b allotype13 (68.4)1.84 (0.68--5.01)P = 0.231ns32 (68.1)1.81 (0.93--3.53)P = 0.079ns ≥1 HNA1c allotype10 (52.6)2.19 (0.86--5.62)P = 0.101ns20 (42.6)1.46 (0.77--2.77)P = 0.243nsP values less than 0.05 are indicated in italics*P* ~*Bonf*~ Bonferroni corrected P value, *OR* odds ratio, *CI* confidence interval, *ns* not statistically significant, --, the variable of interest was not detected in any of the cases and thus could not be analysedTable 5Infant FcγR variants associated with perinatal HIV-1 acquisition after adjusting for confounding variablesTotal infectedIntrapartum infectedUnivariateAdjusted for VL^a^P~Bonf~UnivariateAdjusted for VLP~Bonf~AOR (95 % CI)P valueAOR (95 % CI)P value*FcγRIIa (rs1801274)*Genotype 131HH (ref)11 131HRP = 0.4260.79 (0.38--1.62)P = 0.519nsP = 0.6700.80 (0.27--2.32)P = 0.685ns 131RRP = 0.5160.84 (0.39--1.83)P = 0.657nsP = 0.8950.97 (0.31--2.97)P = 0.951nsAllele carriage ≥1 131H alleleP = 0.8481.01 (0.55--1.85)P = 0.970nsP = 0.8540.89 (0.37--2.12)P = 0.792ns ≥1 131R alleleP = 0.4140.81 (0.41--1.59)P = 0.536nsP = 0.7370.87 (0.32--2.32)P = 0.774ns*FcγRIIb (rs1050501)*Genotype 232II (ref)11 232ITP = 0.5831.29 (0.70--2.39)P = 0.415nsP = 0.8111.40 (0.57--3.44)P = 0.469ns 232TTP = 0.1101.97 (0.89--4.37)P = 0.096nsP = 0.5251.82 (0.56--5.90)P = 0.317nsAllele carriage ≥1 232I alleleP = 0.1320.57 (0.28--1.20)P = 0.140nsP = 0.5540.65 (0.22--1.90)P = 0.429ns ≥1 232T alleleP = 0.2801.46 (0.83--2.57)P = 0.195nsP = 0.6601.50 (0.65--3.47)P = 0.344ns*FcγRIIIa (rs396991)*Genotype 158F/FF/FF (ref)11 158FV/FFV/FVVP = 0.4560.87 (0.49--1.56)P = 0.647nsP = 0.8211.14 (0.49--2.66)P = 0.764ns 158V/VVP = 0.1450.28 (0.08--1.00)P = 0.051nsP = 0.8990.28 (0.03--2.27)P = 0.232nsAllele carriage ≥1 158F alleleP = 0.2723.34 (0.96--11.57)P = 0.058nsP = 0.8193.89 (0.50--30.31)P = 0.194ns ≥1 158V alleleP = 0.1980.75 (0.43--1.31)P = 0.311nsP = 0.9640.95 (0.42--2.19)P = 0.910ns*FcγRIIIb*Genotype HNA1a+/1b−/1c−*P* *=* *0.040*0.37 (0.15--0.92)*P* *=* *0.033*ns*P* *=* *0.035*0.20 (0.04--0.96)*P* *=* *0.044*ns HNA1a−/1b+/1c−P = 0.5650.69 (0.25--1.86)P = 0.459nsP = 0.1600.20 (0.03--1.69)P = 0.139ns HNA1a−/1b−/1c+P = 0.6720.70 (0.18--2.78)P = 0.616ns----P = 0.970 HNA1a+/1b+/1c− (ref)11 HNA1a+/1b−/1c+P = 0.6430.73 (0.31--1.72)P = 0.478nsP = 0.8630.97 (0.33--2.79)P = 0.949ns HNA1a−/1b+/1c+P = 0.2601.57 (0.64--3.88)P = 0.326nsP = 0.2721.80 (0.57--5.71)P = 0.316ns HNA1a+/1b+/1c+P = 0.0862.36 (0.63--8.75)P = 0.201nsP = 0.843--nsP = 0.123Allele carriage ≥1 HNA1a allotypeP = 0.4080.79 (0.43--1.46)P = 0.452nsP = 0.9861.01 (0.40--2.56)P = 0.981ns ≥1 HNA1b allotype*P* *=* *0.020*2.02 (1.12--3.64)*P* *=* *0.019*nsP = 0.0791.91 (0.81--4.53)P = 0.140ns ≥1 HNA1c allotypeP = 0.0751.52 (0.86--2.69)P = 0.146nsP = 0.1101.74 (0.77--3.96)P = 0.185nsIn utero infectedIn utero-enriched infectedUnivariateAdjusted for VL + bwtP~Bonf~UnivariateAdjusted for VLP~Bonf~AOR (95 % CI)P valueAOR (95 % CI)P value*FcγRIIa (rs1801274)*Genotype 131HH (ref)11 131HRP = 0.4560.71 (0.15--3.25)P = 0.657nsP = 0.4550.75 (0.32--1.79)P = 0.520ns 131RRP = 0.5411.87 (0.45--7.79)P = 0.390nsP = 0.4330.77 (0.30--1.96)P = 0.581nsAllele carriage ≥1 131H alleleP = 0.1390.42 (0.15--1.21)P = 0.108nsP = 0.6851.07 (0.51--2.22)P = 0.858ns ≥1 131R alleleP = 0.9121.17 (0.31--4.58)P = 0.817nsP = 0.3960.76 (0.34--1.70)P = 0.503ns*FcγRIIb (rs1050501)*Genotype 232II (ref)11 232ITP = 0.8620.80 (0.23--2.74)P = 0.724nsP = 0.5771.18 (0.56--2.50)P = 0.658ns 232TTP = 0.0383.53 (0.95--13.14)P = 0.060nsP = 0.0922.02 (079--5.16)P = 0.144nsAllele carriage ≥1 232I alleleP = 0.0260.26 (0.08--0.86)*P* *=* *0.028*nsP = 0.1100.54 (0.23--1.28)P = 0.160ns ≥1 232T alleleP = 0.2981.33 (0.47--3.77)P = 0.593nsP = 0.2641.38 (0.70--2.74)P = 0.353ns*FcγRIIIa (rs396991)*Genotype 158F/FF/FF (ref)11 158FV/FFV/FVVP = 0.3910.61 (0.20--1.86)P = 0.385nsP = 0.4100.74 (0.37--1.49)P = 0.405ns 158V/VVP = 0.5500.85 (0.16--4.42)P = 0.842nsP = 0.0730.29 (0.06--1.36)P = 0.117nsAllele carriage ≥1 158F alleleP = 0.3540.93 (0.19--4.53)P = 0.931nsP = 0.1902.91 (0.66--12.92)P = 0.160ns ≥1 158V alleleP = 0.7400.66 (0.23--1.85)P = 0.425nsP = 0.1000.65 (0.33--1.28)P = 0.215ns*FcγRIIIb*Genotype HNA1a+/1b−/1c−P = 0.7090.77 (0.15--3.86)P = 0.748nsP = 0.3500.53 (0.18--1.52)P = 0.234ns HNA1a−/1b+/1c−P = 0.6310.46 (0.04--4.76)P = 0.513nsP = 0.6781.13 (0.37--3.42)P = 0.827ns HNA1a−/1b−/1c+P = 0.9701.48 (0.14--15.83)P = 0.744nsP = 0.5321.33 (0.32--5.54)P = 0.695ns HNA1a+/1b+/1c− (ref)11 HNA1a+/1b−/1c+P = 0.8080.65 (0.10--4.10)P = 0.645nsP = 0.3650.50 (0.15--1.67)P = 0.259ns HNA1a−/1b+/1c+P = 0.0774.47 (0.84--23.80)P = 0.080nsP = 0.5181.50 (0.46--4.92)P = 0.501ns HNA1a+/1b+/1c+P = 0.1233.35 (0.40--27.73)P = 0.262ns*P* *=* *0.017*4.44 (1.14--17.40)*P* *=* *0.032*nsAllele carriage ≥1 HNA1a allotypeP = 0.3070.58 (0.19--1.76)P = 0.337nsP = 0.2580.66 (0.32--1.37)P = 0.265ns ≥1 HNA1b allotypeP = 0.2311.82 (0.63--5.32)P = 0.271nsP = 0.0792.16 (1.05--4.44)*P* *=* *0.037*ns ≥1 HNA1c allotypeP = 0.1012.16 (0.76--6.14)P = 0.149nsP = 0.2431.42 (0.71--2.81)P = 0.321nsP values less than 0.05 are indicated in italics*P* ~*Bonf*~ Bonferroni corrected P value, *AOR* adjusted odds ratio, *CI* confidence interval, *VL* viral load, *bwt* birth weight, --, the variable of interest was not detected in any of the cases and thus could not be analysed^a^The multivariate analysis adjusted for demographic and clinical variables that independently associated with transmission. Due to high correlation with viral load, CD4 T cell counts were not included in the multivariate model

Linkage disequilibrium at the low affinity *FCGR* gene locus {#Sec8}
------------------------------------------------------------

Linkage disequilibrium (LD) between the different FcγR variants could potentially modulate associations observed for the individual FcγRs. Given the strong association of the maternal FcγRIIIa-F158V variant with perinatal HIV-1 transmission, we determined LD in the study cohort (Fig. [2](#Fig2){ref-type="fig"}) and adjusted for its possible confounding effect on the associations observed for FcγRIIIb-HNA1a\|b\|c, FcγRIIa-H131R and FcγRIIb-I232T in the multivariate analysis (Table [6](#Tab6){ref-type="table"}).Fig. 2LD for FcγR variants in the study cohort comprising Black South African HIV-1 infected mothers (*left*) and their infants (*right*). Values and colours reflect r^2^ (× 100) and D′/LOD measures of LD, respectively. The *black triangle* depicts a haplotype block that is indicative of the relationship between the FcγRIIIb-HNA1b and -HNA1c allotypes. Such that HNA1b and HNA1c are identical at amino acid position 65 (p.65S) and differ only at amino acid position 78 (p.78A^1b^\>D^1c^)Table 6Multivariate analysis adjusted FcγRIIIa-F158VMultivariate, not adjusted for FcγRIIIa-F158VP~Bonf~Multivariate analysis with adjustment for FcγRIIIa-F158V genotype and allele carriageF158V genotypeP~Bonf~≥1 158F alleleP~Bonf~≥1 158V alleleP~Bonf~***Maternal****FcγRIIa (rs1801274)*131RR genotype Total transmitting*P* *=* *0.023*ns1.93 (0.82--4.57), P = 0.133ns2.25 (0.97--5.24), P = 0.133ns2.08 (0.89--4.86), P = 0.091ns In utero transmitting*P* *=* *0.029*ns9.37 (1.01--87.22), *P* *=* *0.049*ns9.59 (1.05--87.37), *P* *=* *0.045*ns10.26 (1.12--94.28), *P* *=* *0.040*ns In utero-enriched transmitting*P* *=* *0.048*ns1.94 (0.66--5.70), P = 0.226ns2.60 (0.90--7.52), P = 0.077ns1.98 (0.67--5.80), P = 0.214ns≥1 131H allele In utero transmitting*P* *=* *0.045*ns0.42 (0.14--1.29), P = 0.132ns0.40 (0.14--1.15), P = 0.088ns0.39 (0.13--1.18), P = 0.096ns≥1 131R allele Total transmitting*P* *=* *0.049*ns1.80 (0.84--3.85), P = 0.128ns1.90 (0.89--4.05), P = 0.095ns1.91 (0.90--4.06), P = 0.091ns*FcγRIIb (rs1050501)*232TT genotype Total transmitting*P* *=* *0.030*ns2.06 (0.78--5.41), P = 0.144ns2.48 (0.96--9.36), P = 0.060ns2.17 (0.83--5.67), P = 0.115ns≥1 232I allele Total transmitting*P* *=* *0.043*ns0.49 (0.20--1.20), P = 0.118ns0.43 (0.18--1.05), P = 0.063ns0.48 (0.20--1.18), P = 0.110ns*FcγRIIIb*≥1 HNA1b allotype Total transmitting*P* *=* *0.014*ns2.26 (1.22--4.17), *P* *=* *0.009*ns2.19 (1.20--4.02), *P* *=* *0.011*ns2.21 (1.20--4.11), *P* *=* *0.011*ns In utero-enriched transmitting*P* *=* *0.031*ns2.43 (1.15--5.16), *P* *=* *0.020*ns2.32 (1.11--4.82), *P* *=* *0.025*ns2.40 (1.13--5.10), *P* *=* *0.023*ns***Infant****FcγRIIIb*HNA1a+/1b−/1c− genotype Total infected*P* *=* *0.033*ns0.37 (0.15--0.93), *P* *=* *0.034*ns0.37 (0.15--0.91), *P* *=* *0.031*ns0.37 (0.15--0.93), *P* *=* *0.034*ns Intrapartum infected*P* *=* *0.044*ns0.20 (0.04--0.96), *P* *=* *0.044*ns0.19 (0.04--0.95), *P* *=* *0.043*ns0.20 (0.04--0.96), *P* *=* *0.044*nsHNA1a+/1b+/1c+ genotype In utero-enriched infected*P* *=* *0.032*ns5.67 (1.39--23.11), *P* *=* *0.016*ns4.47 (1.13--17.64), *P* *=* *0.032*ns5.74 (1.39--23.57), *P* *=* *0.015*ns≥1 HNA1b allotype Total infected*P* *=* *0.019*ns2.11 (1.16--3.83), *P* *=* *0.014*ns2.04 (1.12--3.69), *P* *=* *0.019*ns2.08 (1.15--3.77), *P* *=* *0.016*ns In utero-enriched infected*P* *=* *0.037*ns2.29 (1.10--4.76), *P* *=* *0.026*ns2.22 (1.07--4.58), *P* *=* *0.032*ns2.26 (1.09--4.68), *P* *=* *0.028*nsP values less than 0.05 are indicated in italics*P* ~*Bonf*~ Bonferroni corrected P value, *AOR* adjusted odds ratio, *CI* confidence interval, *VL* viral load, *bwt* birth weight, *ns* not statistically significant--, the variable of interest was not detected in any of the cases and thus could not be analysed

To determine LD for the FcγRIIIb-HNA1a\|b\|c allotypes, we used, as a tag-variant, one of four amino acid changes that differentiate HNA1a from HNA1b and HNA1c (p.N^a^65S^bc^, rs448740) as well as the variant that differentiates HNA1c from HNA1a and HNA1b (p.A^ab^78D^c^, rs5030738). The maternal FcγRIIIb-N^a^65S^bc^ variant was not in LD with FcγRIIIa-F158V (P = 0.057, D′ = 0.189, r^2^ = 0.020), while the p.A^ab^78D^c^ variant was in moderate LD with FcγRIIIa-F158V (P = 0.024, D′ = 0.471, r^2^ = 0.029) with the FcγRIIIa-158V allele overrepresented in individuals bearing an FcγRIIIb-78A allele (HNA1c individuals) compared to FcγRIIIb-78DD individuals (59 vs. 20 %). Following adjustment for FcγRIIIa-F158V in the multivariate analysis, the associations previously observed for the FcγRIIIb-HNA1b allotype strengthened for both the total and in utero-enriched transmitting groups (Table [6](#Tab6){ref-type="table"}). Similarly, significance was retained in the infants with associations strengthening for the FcγRIIIb-HNA1a+\|1b+\|1c+ genotype in the in utero-enriched infected group and carriage of an HNA1b allotype in the total infected and in utero-enriched infected groups (Table [6](#Tab6){ref-type="table"}). Overall, this suggests that the observed associations between the FcγRIIIb-HNA1a\|b\|c variant and perinatal HIV-1 transmission are not only independent of FcγRIIIa-F158V, but also potentially negatively confounded by FcγRIIIa-F158V.

Both maternal FcγRIIa-H131R and FcγRIIb-I232T was in moderate LD with FcγRIIIa-F158V (P \< 0.0001, D′ = 0.351, r^2^ = 0.077 and P = 0.002, D′ = 0.448, r^2^ = 0.052, respectively), with the FcγRIIIa-158V allele overrepresented in individuals bearing an FcγRIIa-131H allele compared to FcγRIIa-131RR individuals (66 vs. 39 %) and in individuals bearing an FcγRIIb-232I allele compared to FcγRIIb-232TT individuals (59 vs. 39 %). When adjusted for FcγRIIIa-F158V in the multivariate analysis, all associations for the FcγRIIa-H131R and FcγRIIb-I232T weakened with the majority losing significance (Table [6](#Tab6){ref-type="table"}). This suggests that the associations observed for FcγRIIa-H131R and FcγRIIb-I232T potentially resulted from LD with FcγRIIIa-F158V.

Discussion {#Sec9}
==========

The extent to which FcγR-mediated effector mechanisms contribute to the risk of HIV-1 transmission and acquisition is currently undefined. Through the study of FcγR functional variants we indirectly demonstrated a role for FcγR-mediated effector functions in modulating perinatal HIV-1 transmission and acquisition. Our findings indicate that the FcγRIIIa-F158V variant that alters antibody binding affinity and functional capacity is associated with infectiousness of an HIV-1 infected mother, while the FcγRIIIb-HNA1a\|b\|c variant that affects neutrophil effector function is associated with both maternal infectiousness and infant susceptibility.

The significance of FcγR-mediated effector functions in maintaining immune homeostasis is validated by the association of functionally significant FcγR variants with immune disorders \[[@CR18]\]. Here we describe an association between the high binding FcγRIIIa allele and reduced maternal infectiousness in perinatal transmission of HIV-1. In particular, carriage of the FcγRIIIa-158V allele by the mother was associated with \~50 % reduction in the odds of HIV-1 transmission. The significant association in the in utero-enriched transmission group, but not in the intrapartum group, suggests that the underlying mechanism may be more pronounced at the maternofoetal interface. FcγRIIIa-bearing leukocytes, including natural killer cells, macrophages and γδ T lymphocytes, are readily recruited to the decidua where they likely contribute to eliminating cell-associated HIV-1 through ADCC \[[@CR19], [@CR20]\]. While decidual natural killer cells are primarily FcγRIIIa negative during a healthy pregnancy, they likely upregulate FcγRIIIa expression in the presence of HIV-1 as demonstrated for other perinatally transmitted viruses---human cytomegalovirus and hepatitis C virus \[[@CR21], [@CR22]\]. Since cell-associated HIV-1 is thought to be more infectious in utero compared to cell-free virus \[[@CR23]\], ADCC-mediated killing of HIV-1 infected cells may contribute to protective immunity at the maternofoetal interface. Of consequence, the FcγRIIIa-F158V variant impacts on ADCC capacity, such that the FcγRIIIa-158V allele exhibits enhanced IgG binding and ADCC capacity compared to the FcγRIIIa-158F allele \[[@CR7], [@CR24]\]. The decreased in utero transmission risk associated with the FcγRIIIa-158V allele suggests that the enhanced ADCC capacity conferred by this variant may potentiate elimination of cell-associated HIV-1 and reduce the odds of HIV-1 crossing the placenta through cell--cell interactions. However, the role of ADCC and other potential FcγRIIIa-mediated immune mechanisms---systemic or localized---in perinatal HIV-1 transmission needs to be further elucidated.

In contrast to that observed for the FcγRIIIa-F158V variant, an association between the FcγRIIIb-HNA1a\|b\|c allotype and perinatal HIV-1 transmission was observed in both the mother and infant. The different FcγRIIIb allotypes arise from multiple amino acid substitutions that do not alter antibody binding affinity, but affect the glycosylation and tertiary structure of the receptor \[[@CR9], [@CR24]--[@CR26]\]. Neutrophils from FcγRIIIb-HNA1a homozygous donors have an enhanced phagocytic and respiratory burst capacity compared to neutrophils from FcγRIIIb-HNA1b homozygous donors \[[@CR27], [@CR28]\]. In the present study, homozygosity for the FcγRIIIb-HNA1a allotype in the infant was associated with reduced odds of HIV-1 acquisition compared to other allotype combinations. In both mother and infant, carriage of at least one FcγRIIIb-HNA1b allotype was associated with increased odds of HIV-1 acquisition. Since expression of FcγRIIIb is largely restricted to neutrophils, these findings suggest a potential role for neutrophil-mediated FcγR effector functions in modulating perinatal HIV-1 transmission and acquisition. The underlying mechanism may also involve basophils as FcγRIIIb is detected at low levels on a subset of this cell population, although its function here is unknown.

To date, only the FcγRIIa-H131R variant has been studied in perinatal HIV-1 transmission, with an association reported between the FcγRIIa-131HH genotype and increased infant susceptibility \[[@CR29]\]. This association was however not observed in the present study. The contrasting findings are likely attributable to study design. In the Brouwer et al. study, infants were considered perinatally infected if PCR positive at or before 4 months of age where in the present study infant infection status was determined up to 6 weeks of age. The implication thereof is that the number of infants that acquired HIV-1 through breastfeeding is likely higher in the Brouwer et al. study compared to the 12.8 % in the present study. If this is the case, the findings of the Brouwer et al. study may be more representative of an association with HIV-1 transmission through breastfeeding, rather than in utero or intrapartum transmission.

Perinatal HIV-1 transmission is an attractive model in which to study the role of antibodies and their effector functions in HIV-1 protective immunity. This represents a natural situation where the individual at risk is passively immunized with HIV-1-specific antibodies through transplacental transfer of IgG \[[@CR30], [@CR31]\]. This model also affords the opportunity to study both members of the transmitting dyad, allowing the assessment of factors contributing to the infectiousness of the transmitter (mother) as well as the susceptibility of the recipient (infant). The findings of this study therefore not only highlight additional immunological factors associated with risk of perinatal HIV-1 transmission, but further support a role for FcγR-mediated effector functions in HIV-1 protective immunity. In particular, findings underscore a potential involvement of neutrophils in protection from HIV-1 transmission and a possible role of FcγR-mediated effector functions in modulating the infectiousness of an HIV-1 infected individual. The significance of these findings in the context of sexual transmission will need to be determined.

There are a number of limitations of the current study and areas that require further investigation. Due to the small sample size and number of comparisons performed it is likely that a number of associations are due to chance. However, since the adjustment for multiple comparisons eliminate type I errors at the cost of type 2 errors, we considered it more important to identify potential factors that may play a role in perinatal HIV-1 transmission rather than dismissing these leads as chance variations brought about by multiple comparisons. Nonetheless, when a Bonferroni correction is applied (α = 0.0012), the association with the maternal FcγRIIIa-F158V variant in the in utero-enriched transmitting group remains significant.

Conclusions {#Sec10}
===========

The maternal and infant immune mechanisms involved in modulating the risk of perinatal HIV-1 transmission and acquisition are complex and multifactorial. Using the approach of studying FcγR genetic variants as proxy for functional capability, this study has revealed the potential importance of FcγR-mediated immune mechanisms that likely involve FcγRIIIa-bearing immune cells and neutrophils. The findings of this study need to be validated in larger cohorts, in particular associations that did not retain significance following adjustment for multiple comparisons. Moreover, understanding the role of IgG Fc-mediated mechanisms requires an appreciation for the collective contribution of multiple components in addition to FcγR genetic variants. These include factors such as the magnitude and specificity of maternal HIV-1 specific antibodies, the efficiency of antibody transfer across the placenta, immune cell phenotypes at the sites of HIV-1 exposure, and the impact of the overall immune environment and state of activation on maternal and infant immune responses.

Methods {#Sec11}
=======

Study populations {#Sec12}
-----------------

All study participants were Black South African individuals. Ethical clearance was obtained from the University of the Witwatersrand Human Research Ethics Committee and the Institutional Review Board of Columbia University. Written informed consent was obtained from all participants.

Cohort HIV-1 infection status {#Sec13}
-----------------------------

Maternal HIV-1 RNA levels were determined using the Roche Amplicor RNA Monitor assay version 1.5 (Roche Diagnostic Systems, Inc., Branchburg, New Jersey, USA). CD4^+^ T cell counts were determined using the FACSCount System from Becton--Dickinson (San Jose, CA, USA). Infant samples were tested for HIV-1 DNA using the Roche Amplicor Monitor version 1.5 qualitative PCR assay (Roche Diagnostic Systems).

*FCGR* gene copy number variability and nucleotide variant detection {#Sec14}
--------------------------------------------------------------------

Genomic DNA was extracted from EDTA anticoagulated blood samples using the QIAamp DNA Mini Kit (Qiagen, Dusseldorf, Germany). Functional *FCGR* variants were genotyped using the *FCGR*-specific multiplex ligation-dependent probe amplification (MLPA) assay (MRC Holland, Amsterdam, The Netherlands) according to manufacturer's instructions \[[@CR19], [@CR20]\]. The assay detects the genomic copy number of the *FCGR2C*, *FCGR3A* and *FCGR3B* genes and known functional allelic variants that include FcγRIIa-H131R; FcγRIIb-I232T, FcγRIIIa-F158V, FcγRIIIb-HNA1a\|b\|c, *FCGR2C* expression variants (p.X57Q and c.798+1A\>G), and the *FCGR2B/C* promoter variants (c.-386G\>C and c.-120T\>A). Genotypes assigned to study participants according to the MLPA assay were confirmed on randomly selected samples with nucleotide sequencing or TaqMan^®^ SNP Genotyping Assays (Thermofisher, Life Technologies, Foster City, USA).

Computational and statistical analysis {#Sec15}
--------------------------------------

Univariate analyses were used to determine the association between FcγR functional variants and perinatal HIV-1 transmission. Multivariate logistic regression was used to adjust for available confounders that were independently significantly associated with HIV-1 transmission i.e. viral load (all groups) and birth weight (in utero transmitting group) (Table [1](#Tab1){ref-type="table"}). Due to high correlation with viral load, CD4 T^+^ cell count was not included in the multivariate model. The *t* test was used to compare normally distributed continuous variables and the Fisher's exact test for categorical data. All analyses were performed in STATA version 10.1 (StataCorp LP, College Station, USA) and a P value of less than 0.05 was considered statistically significant. Adjustment for multiple comparisons was performed using the Bonferroni correction, which considered 42 independent tests---mothers and infants, three unrelated clinical subgroups, and seven loci (*FCGR3A* gene copy number, *FCGR3B* gene copy number, FcγRIIa-H131R, FcγRIIb-I232T, FcγRIIIa-F158V, FcγRIIIb-HNA1a\|b\|c, and overall FcγR variability profiles).

LD between pairs of biallelic loci was tested using an expectation--maximization likelihood-ratio test with 16 000 permutations (significance level \<0.05) in Arlequin ver 3.5.2.2 \[[@CR32]\]. LD coefficients (D′ and r^2^) were determined in Haploview \[[@CR33]\]. Only individuals bearing two copies of each low affinity *FCGR* gene were considered. LD with FcγRIIIb-HNA1a\|b\|c was assessed using two loci: rs448740 (p.N65S; as tag-variant) that differentiates HNA1a (p.65 N) from HNA1b\|c (p.65S) and rs5030738 (p.A78D) that differentiates HNA1a\|b (p.78A) from HNA1c (p.78D).

Additional files {#Sec16}
================

10.1186/s12977-016-0272-y Associations of maternal and infant *FCGR3A* and *FCGR3B* gene copy number with perinatal HIV-1 transmission. Univariate and multivariate analysis of associations of maternal and infant *FCGR3A* and *FCGR3B* gene copy number with perinatal HIV-1 transmission.10.1186/s12977-016-0272-y Association of the FcγRIIIb-HNA1a homozygous genotype with perinatal HIV-1 acquisition when compared to other combinations of FcγRIIIb-HNA allotypes. Univariate and multivariate analysis of associations of the FcγRIIIb-HNA1a homozygous genotype with perinatal HIV-1 acquisition when compared to other combinations of FcγRIIIb-HNA allotypes.
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:   antibody-dependent cellular cytotoxicity
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:   antibody-dependent cellular phagocytosis
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:   adjusted odds ratio

CI
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DNA

:   deoxyribonucleic acid
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FcγR
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:   multiplex ligation-dependent probe amplification

PCR

:   polymerase chain reaction

RNA

:   ribonucleic acid

sdNVP

:   single dose nevirapine

RL performed the researched and wrote the paper. AM and RL performed data analysis. GG recruited patients and acquired clinical data. LK contributed to the design of the study. CT designed the study and supervised the research. All co-authors critically revised the manuscript for intellectual content. All authors read and approved the manuscript.

Acknowledgements {#FPar1}
================

The authors thank the study participants and Dorothy Southern for her review of the manuscript. This work is based on the research supported by grants from NICHD (HD 42402), the South African Medical Research Council and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation. Ria Lassauniere is the recipient of bursaries from the South African National Research Foundation, the Poliomyelitis Research Foundation and a University of the Witwatersrand postgraduate merit award.

*Disclaimer*: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.
